Left Ventricular Dysfunction in Cancer Treatment
Authors:
- 1 February 2018
- journal article
- review article
- Published by Elsevier in JACC: Heart Failure
- Vol. 6 (2) , 87-95
Abstract
No abstract availableKeywords
Funding Information
- Genentech, Inc.
This publication has 45 references indexed in Scilit:
- Emerging Paradigms in Cardiomyopathies Associated With Cancer TherapiesCirculation Research, 2013
- ERBB2 Inhibition and Heart FailureNew England Journal of Medicine, 2012
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and TrastuzumabCirculation: Cardiovascular Imaging, 2012
- Decline in the Use of Anthracyclines for Breast CancerJournal of Clinical Oncology, 2012
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI: Journal of the National Cancer Institute, 2010
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985